Key result
Renin-angiotensin-aldosterone system inhibition has fundamentally shaped the management of cardiovascular and renal disease, with ongoing discoveries promising further development of selective drugs.
A narrative review highlighting the historical discovery and ongoing clinical importance of renin-angiotensin-aldosterone system blockade in cardiovascular and renal disease.
Sustains RAAS blockade as core therapy in cardiovascular and renal disease; leaves open development of selective inhibitors.
The existence of the renin-angiotensin-aldosterone system was first postulated over 100 years ago. Following the identification of all the major components, came the discovery of their potential pathogenicity in cardiovascular and renal disease. The introduction of drugs that inhibit the synthesis or actions of this system has prompted a number of trials that have largely shaped how cardiovascular and renal disease is managed today. The continued discovery of yet more components of this system promises to further our understanding of its influence on disease processes and herald the development of more highly selective drugs, ensuring that the renin-angiotensin-aldosterone system will continue to be a key area of interest for many years to come.
No takes yet. Share an insight, caveat, or question.
Benavente et al. (2010) conducted a review in Cardio-renal disease. Renin-angiotensin blockade was evaluated. Renin-angiotensin-aldosterone system inhibition has fundamentally shaped the management of cardiovascular and renal disease, with ongoing discoveries promising further development of selective drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: